These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 25208139

  • 21. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T, Chiba M, Ohyama S, Yoshida-Yoshimioto R, Fujii K, Hosaka H, Goto-Shimazaki H, Kadotani A, Ohe T, Lin S, Langdon RB, Berger JP.
    Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
    [Abstract] [Full Text] [Related]

  • 22. Preclinical pharmacokinetics, pharmacodynamics, and toxicity of novel small-molecule GPR119 agonists to treat type-2 diabetes and obesity.
    Patil M, Casari I, Thapa D, Warne LN, Dallerba E, Massi M, Carlessi R, Falasca M.
    Biomed Pharmacother; 2024 Aug; 177():117077. PubMed ID: 38968799
    [Abstract] [Full Text] [Related]

  • 23. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
    Zhang JK, Li AR, Yu M, Wang Y, Zhu J, Kayser F, Medina JC, Siegler K, Conn M, Shan B, Grillo MP, Eksterowicz J, Coward P, Liu JJ.
    Bioorg Med Chem Lett; 2013 Jun 15; 23(12):3609-13. PubMed ID: 23648181
    [Abstract] [Full Text] [Related]

  • 24. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
    Semple G, Lehmann J, Wong A, Ren A, Bruce M, Shin YJ, Sage CR, Morgan M, Chen WC, Sebring K, Chu ZL, Leonard JN, Al-Shamma H, Grottick AJ, Du F, Liang Y, Demarest K, Jones RM.
    Bioorg Med Chem Lett; 2012 Feb 15; 22(4):1750-5. PubMed ID: 22264481
    [Abstract] [Full Text] [Related]

  • 25. GPR119 agonists 2009-2011.
    Buzard DJ, Lehmann J, Han S, Jones RM.
    Pharm Pat Anal; 2012 Jul 15; 1(3):285-99. PubMed ID: 24236842
    [Abstract] [Full Text] [Related]

  • 26. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
    Kang SU.
    Drug Discov Today; 2013 Dec 15; 18(23-24):1309-15. PubMed ID: 24060477
    [Abstract] [Full Text] [Related]

  • 27. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
    Alper P, Azimioara M, Cow C, Mutnick D, Nikulin V, Michellys PY, Wang Z, Reding E, Paliotti M, Li J, Bao D, Zoll J, Kim Y, Zimmerman M, Groessel T, Tuntland T, Joseph SB, McNamara P, Seidel HM, Epple R.
    Bioorg Med Chem Lett; 2014 May 15; 24(10):2383-7. PubMed ID: 24751443
    [Abstract] [Full Text] [Related]

  • 28. Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119.
    Park EY, Kim EH, Kim CY, Kim MH, Choung JS, Oh YS, Moon HS, Jun HS.
    PLoS One; 2016 May 15; 11(7):e0158796. PubMed ID: 27391814
    [Abstract] [Full Text] [Related]

  • 29. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
    Wang Y, Yu M, Zhu J, Zhang JK, Kayser F, Medina JC, Siegler K, Conn M, Shan B, Grillo MP, Liu JJ, Coward P.
    Bioorg Med Chem Lett; 2014 Feb 15; 24(4):1133-7. PubMed ID: 24440299
    [Abstract] [Full Text] [Related]

  • 30. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
    Yu M, Ken Zhang J, Wang Y, Zhu J, Kayser F, Medina JC, Siegler K, Conn M, Shan B, Grillo MP, Coward P, Jim Liu J.
    Bioorg Med Chem Lett; 2014 Jan 01; 24(1):156-60. PubMed ID: 24332491
    [Abstract] [Full Text] [Related]

  • 31. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
    Overton HA, Fyfe MC, Reynet C.
    Br J Pharmacol; 2008 Mar 01; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
    [Abstract] [Full Text] [Related]

  • 32. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 Mar 01; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 33. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice.
    Zhang M, Feng Y, Wang J, Zhao J, Li T, He M, Yang D, Nosjean O, Boutin J, Renard P, Wang MW.
    PLoS One; 2013 Mar 01; 8(5):e63861. PubMed ID: 23704946
    [Abstract] [Full Text] [Related]

  • 34. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
    Hryciw DH, Patten RK, Rodgers RJ, Proietto J, Hutchinson DS, McAinch AJ.
    Expert Opin Investig Drugs; 2024 Mar 01; 33(3):183-190. PubMed ID: 38372052
    [Abstract] [Full Text] [Related]

  • 35. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC, McCormack JG, Overton HA, Procter MJ, Reynet C.
    Expert Opin Drug Discov; 2008 Apr 01; 3(4):403-13. PubMed ID: 23489096
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
    Brocklehurst KJ, Broo A, Butlin RJ, Brown HS, Clarke DS, Davidsson Ö, Goldberg K, Groombridge SD, Kelly EE, Leach A, McKerrecher D, O'Donnell C, Poucher S, Schofield P, Scott JS, Teague J, Westgate L, Wood MJ.
    Bioorg Med Chem Lett; 2011 Dec 15; 21(24):7310-6. PubMed ID: 22061639
    [Abstract] [Full Text] [Related]

  • 39. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.
    Semple G, Ren A, Fioravanti B, Pereira G, Calderon I, Choi K, Xiong Y, Shin YJ, Gharbaoui T, Sage CR, Morgan M, Xing C, Chu ZL, Leonard JN, Grottick AJ, Al-Shamma H, Liang Y, Demarest KT, Jones RM.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):3134-41. PubMed ID: 21444206
    [Abstract] [Full Text] [Related]

  • 40. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.
    Scott JS, Birch AM, Brocklehurst KJ, Broo A, Brown HS, Butlin RJ, Clarke DS, Davidsson O, Ertan A, Goldberg K, Groombridge SD, Hudson JA, Laber D, Leach AG, Macfaul PA, McKerrecher D, Pickup A, Schofield P, Svensson PH, Sörme P, Teague J.
    J Med Chem; 2012 Jun 14; 55(11):5361-79. PubMed ID: 22545772
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.